Procedural revenue for PM&R: EMG, BoNT, MSK injections, ultrasound

EMG/NCS: The Foundational PM&R Procedure

Electromyography and nerve conduction studies are the bread and butter of many PM&R practices. They are diagnostic, require significant cognitive input, and can be a consistent source of revenue. The key to financial success with EMG/NCS lies in operational efficiency and understanding payer-specific nuances.

An EMG with a limited study of one extremity (CPT 95885) might reimburse in the $150-$250 range, while a more comprehensive study of one extremity (CPT 95886) can be in the $250-$400 range. A complete study involving 3-4 extremities and paraspinals (e.g., CPT 95886 x 2 + 95887) can approach or exceed $1,000, depending on your payer mix. These are just ballpark figures; the real numbers are locked in your contracts.

There are two primary operational models:

• Physician-Only: You perform the entire study, from nerve conduction to needle examination. This maximizes your direct control over quality but caps your volume. It’s a good model for a solo practitioner or someone building a reputation for high-quality, complex neuromuscular diagnostics.
• Physician + Tech: A trained technician performs the NCS portion, with the physician performing the needle EMG and providing the final interpretation. This model allows for higher throughput. While you have to pay the tech, you can often run two rooms simultaneously, significantly increasing your daily procedural volume. The physician must still be immediately available for supervision.

The biggest pitfall is under-coding or poor documentation. Your report must justify the medical necessity for every limb and muscle tested. A templated report that clearly lists the nerves studied, latencies, amplitudes, and muscles sampled (with findings on insertional activity, spontaneous activity, and motor unit potentials) is your best defense against down-coding or denials. To truly optimize this, you need to know what your major commercial payers are actually paying. This is where having robust data becomes critical; tools that provide CenterIQ rate intelligence can benchmark your current contracts against local market rates, giving you the leverage you need during negotiations.

Botulinum Toxin (BoNT): High-Value, High-Complexity

Botulinum toxin injections represent a significant step up in both clinical complexity and revenue potential. The two most common applications in PM&R are for spasticity management and chronic migraine.

The reimbursement model is twofold: payment for the procedure (the injection) and payment for the drug itself (the “J-code”).

• Procedural Codes: For spasticity, you’ll use codes like 64642-64647 depending on the number of muscles injected per extremity, often with ultrasound guidance (76942). For chronic migraine, the protocol is more standardized under CPT 64615. The procedural payment alone can be several hundred dollars.
• Drug Codes (Buy-and-Bill): This is where the economics get interesting. You purchase the toxin (e.g., Botox, Dysport, Xeomin) upfront and bill the patient’s insurance for it using a specific J-code (e.g., J0585 for onabotulinumtoxinA). Insurers typically reimburse you for the drug at a rate higher than your acquisition cost, often based on the Average Sales Price (ASP) plus a percentage (e.g., ASP + 6%). This margin is designed to cover your storage, handling, and financing costs.

The “buy-and-bill” model introduces inventory risk. A 100-unit vial of Botox can cost your practice over $600. If a patient no-shows or insurance denies the claim after the fact, you bear that cost. Meticulous prior authorization is non-negotiable. Your staff must become experts at submitting the required documentation—chart notes proving failed conservative therapies, spasticity scores like the Modified Ashworth Scale, or headache diaries for migraine—to secure approval before you order or open the vial.

Most of us learned this the hard way: a single denied BoNT claim can wipe out the profit from five or six successful ones. Streamlining your prior authorization workflow is the single most important operational step to making BoNT a reliable revenue center.

MSK Injections and the Ultrasound Multiplier

Musculoskeletal injections are a high-volume, relatively low-overhead procedural service. Common joint injections for osteoarthritis or inflammatory conditions (e.g., knee, shoulder) are coded with CPTs like 20610 (major joint) or 20605 (intermediate joint). While the payment for the injection itself is modest (often $50-$100), the real value comes from two sources: ultrasound guidance and viscosupplementation.

Ultrasound Guidance (CPT 76942): Adding real-time ultrasound guidance is now the standard of care for many injections, particularly for deeper structures like the hip. It improves accuracy, enhances safety, and justifies a separate CPT code. CPT 76942 (Ultrasonic guidance for needle placement) can add $75-$150+ to the total reimbursement for the encounter. To bill for it, you must document the use of ultrasound in your note and save a permanent image of the needle in the target location for the medical record. Proficiency with ultrasound is a skill that pays for itself many times over.

Viscosupplementation: Like BoNT, this is another buy-and-bill opportunity. You purchase the hyaluronic acid product (e.g., Synvisc, Euflexxa) and bill the J-code along with the injection code (20610). The margins can be attractive, but it carries the same inventory risks. Payer policies are notoriously specific, often requiring proof of failed NSAIDs, physical therapy, and prior corticosteroid injections. Some payers may even have a preferred product.

As your procedural volume grows, you might contemplate creating a dedicated procedure suite or even a small specialty ambulatory surgery center. This is a major strategic decision with significant capital costs and regulatory hurdles. Getting expert guidance on the financial modeling and operational planning is crucial. An ASC/OBL feasibility advisory engagement can help determine if the potential return on investment justifies the complexity and risk for your specific practice and market.

The 199A QBI Deduction: A Narrow Path for Practice Owners

Generating procedural revenue is only half the battle. The next challenge is navigating a tax code that penalizes high-income service professionals. The Qualified Business Income (QBI) deduction, created by Section 199A of the tax code, is a prime example.

In theory, it’s fantastic: a 20% deduction on income from pass-through businesses like a solo practice, S-corp, or partnership. The problem? Medicine is classified as a “Specified Service Trade or Business” (SSTB). For SSTBs, the deduction is phased out and then eliminated entirely once your taxable income exceeds certain thresholds.

For 2026, those thresholds are projected to be around $394,000 for single filers and $787,000 for those married filing jointly. Many PM&R physicians with a successful private practice will find themselves above this limit, losing a deduction that could be worth tens of thousands of dollars.

The Strategy: AGI Management. If your income is hovering near the phase-out range, you can take active steps to reduce your Adjusted Gross Income (AGI) and slide back under the threshold. The playbook is straightforward:

1. Max Out Pre-Tax Retirement Accounts: Contribute the absolute maximum to your 401(k) or other workplace retirement plan. This directly reduces your taxable income.
2. Utilize an HSA: If you have a high-deductible health plan, max out your Health Savings Account ($8,750 for a family in 2026). This is another above-the-line deduction.
3. Consider a Cash Balance Plan: For high-income practice owners, this is the super-weapon. A defined-benefit cash balance plan can allow you to contribute an additional $100,000, $200,000, or even more pre-tax, drastically lowering your AGI and potentially preserving the full 199A deduction.

The trap is passivity. If you just let your accountant run the numbers in April, it’s too late. AGI management for 199A requires proactive planning throughout the year.

Rescuing Lost Deductions with 1099 Side Income

For the many physiatrists employed by large hospital systems, the tax landscape is even bleaker. The Tax Cuts and Jobs Act of 2017 (TCJA) eliminated the miscellaneous itemized deduction for unreimbursed employee expenses. This means your professional costs—CME, board exam fees, license and DEA renewals, scrubs, home office equipment—are no longer deductible against your W-2 income.

This is a significant financial hit, costing the average physician thousands of dollars per year. The fix is surprisingly simple: generate any amount of 1099 independent contractor income.

Here’s how it works: That side income—from telemedicine, consulting, medical directorships, expert witness work, or even a single locums shift—is reported on a Schedule C, “Profit or Loss from Business.” This small business entity is now entitled to deduct all “ordinary and necessary” business expenses. Suddenly, all those non-deductible W-2 expenses have a home. Your CME, your state license fee, your professional society dues—they can all be deducted against your 1099 income.

The key insight is that the expenses don’t have to be *exclusively* for the 1099 work. As long as they are also relevant to your independent work (e.g., your medical license is required for both your W-2 job and your telemedicine gig), they are generally deductible. This strategy can effectively make a few thousand dollars of side work unlock five figures worth of deductions, often wiping out the tax liability on the side income and then some.

The planning trap is commingling funds. You must keep separate, clean records for your Schedule C business. Open a dedicated bank account for your 1099 income and expenses. Use a separate credit card for all business-related purchases. This makes bookkeeping trivial and your deductions far more defensible in an audit.

The HSA Triple-Stack: Your Best Long-Term Shelter

While not directly related to procedural revenue, no financial discussion for a working physician is complete without highlighting the Health Savings Account (HSA). It is, without question, the most powerful tax-advantaged investment vehicle available, and it’s particularly valuable for high-income W-2 employees who have fewer levers to pull.

The HSA offers a unique triple tax advantage:

1. Tax-Deductible Contributions: The money you put in is deducted from your income, lowering your current tax bill. For 2026, the family contribution limit is $8,750.
2. Tax-Free Growth: Unlike a 401(k) or IRA, the money inside the HSA grows completely tax-free when invested. You can, and should, invest your HSA funds in low-cost index funds for the long term.
3. Tax-Free Withdrawals: You can withdraw the money tax-free at any time to pay for qualified medical expenses.

The Stacking Strategy: The pro-level move is to *not* use your HSA for current medical bills. Instead, pay for those out-of-pocket and keep the receipts. Let your HSA balance grow and compound tax-free for decades. When you retire, you can reimburse yourself tax-free for all those accumulated medical expenses from years or even decades prior. The receipts effectively become a pool of tax-free money you can access at will. Any funds not used for medical expenses can be withdrawn in retirement like a traditional IRA (subject to income tax, but penalty-free after age 65).

The trap here is treating the HSA like a checking account for co-pays. Many physicians leave their HSA funds in cash, missing out on decades of tax-free market growth. The goal is to max it, invest it, and save every single medical receipt in a digital folder, creating a powerful “shadow” Roth IRA for healthcare costs in retirement.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 7, 2026